RVP Share Price | Retractable Technologies, Inc. Stock Analysis & Recommendation

Q: What does Retractable Technologies, Inc. do?

Overview:Retractable Technologies, Inc. designs, develops, and manufactures safety medical products for the healthcare industry, operating within the Pharmaceuticals & Biotechnology sector and categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) Market cap: USD 19.56 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.45 Return on Equity: -32.28% Price to Book: 0.26Contact Details:Address: 511 Lobo Ln, LITTLE ELM TX: 75068-5295 Tel: 1 972 2941010 Fax: 1 972 2923600

Q: Is Retractable Technologies, Inc. overvalued or undervalued?

As of 15 May 2023, the valuation grade for Retractable Technologies, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company is considered overvalued given its negative earnings and poor return metrics. Key valuation ratios include a Price to Book Value of 0.26, an EV to EBIT of 0.64, and an EV to EBITDA of 0.96, all of which suggest that the company's valuation is not supported by its financial performance.In comparison to its peers, Retractable Technologies, Inc. has a significantly lower EV to EBITDA ratio than Delcath Systems, Inc. at 60.33 and Neuronetics, Inc. at -7.61, highlighting its relative underperformance in the market. Additionally, while the company has shown a positive return of 20.35% year-to-date, it still lags behind the S&P 500's return of 12.22% during the same period, and its long-term performance has been notably poor with a 5-year return of -88.89% compared to the S&P 500's 96.61%.

Q: Is Retractable Technologies, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Retractable Technologies, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Daily moving averages are also bullish, while the weekly Bollinger Bands indicate a bullish stance, although the monthly Bollinger Bands are bearish. The KST shows a bullish signal on the weekly and mildly bullish on the monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.16% and 3.51% compared to the S&P 500's 1.05% and 2.33%, respectively. However, the longer-term returns are concerning, with a 1-year return of -6.96% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

44.47 k

Shareholding (Sep 2025)

FII

0.20%

Held by 6 FIIs

DII

96.81%

Held by 3 DIIs

Promoter

0.00%

How big is Retractable Technologies, Inc.?

22-Jun-2025

As of Jun 18, Retractable Technologies, Inc. has a market capitalization of 19.56 million and reported net sales of 33.75 million with a net profit of -22.81 million over the latest four quarters. Shareholder's funds are 87.17 million, and total assets amount to 160.72 million.

View full answer

What does Retractable Technologies, Inc. do?

22-Jun-2025

Retractable Technologies, Inc. designs and manufactures safety medical products for the healthcare sector. As of March 2025, it reported net sales of $8 million and a net loss of $11 million, with a market cap of $19.56 million.

View full answer

Who are in the management team of Retractable Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of Retractable Technologies, Inc. includes Mr. Thomas Shaw as Chairman, President, and CEO, and Mr. John Fort as Vice President, CFO, Treasurer, and Director, along with several independent directors.

View full answer

Is Retractable Technologies, Inc. overvalued or undervalued?

20-Sep-2025

As of May 15, 2023, Retractable Technologies, Inc. is considered overvalued and risky due to negative earnings and poor return metrics, with key ratios indicating underperformance compared to peers and a significant long-term decline in stock value.

View full answer

Is Retractable Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Retractable Technologies, Inc. shows a mildly bullish trend supported by positive MACD signals and moving averages, despite longer-term underperformance compared to the S&P 500.

View full answer

Compare Retractable Technologies, Inc. with Similar Stocks

Precision Optics Corp., Inc.electroCore, Inc.BioSig Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 21 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.43

Return on Equity

-18.91%

Price to Book

0.28

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-94.11%

6 Months

-77.16%

1 Year

-42.73%

2 Years

2.19%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Retractable Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-4.10%

EBIT Growth (5y)

-239.07%

EBIT to Interest (avg)

11.61

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.45

Sales to Capital Employed (avg)

0.44

Tax Ratio

60.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.17%

ROCE (avg)

57.80%

ROE (avg)

21.39%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.26

EV to EBIT

0.64

EV to EBITDA

0.96

EV to Capital Employed

-0.35

EV to Sales

-0.43

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-32.28%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 6 Schemes (3.0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 25.30% vs -8.79% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 99.05% vs -376.32% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.40",
          "val2": "8.30",
          "chgp": "25.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-2.80",
          "chgp": "-17.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.50",
          "val2": "-7.20",
          "chgp": "148.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.10",
          "val2": "-10.50",
          "chgp": "99.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-491.20%",
          "val2": "-563.80%",
          "chgp": "7.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -24.31% vs -54.01% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -70.00% vs -237.25% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.00",
          "val2": "43.60",
          "chgp": "-24.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.50",
          "val2": "-4.00",
          "chgp": "-237.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.80",
          "val2": "-10.50",
          "chgp": "202.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-7.00",
          "chgp": "-70.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-638.60%",
          "val2": "-263.50%",
          "chgp": "-37.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

10.40

8.30

25.30%

Operating Profit (PBDIT) excl Other Income

-3.30

-2.80

-17.86%

Interest

0.00

Exceptional Items

3.50

-7.20

148.61%

Consolidate Net Profit

-0.10

-10.50

99.05%

Operating Profit Margin (Excl OI)

-491.20%

-563.80%

7.26%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 25.30% vs -8.79% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 99.05% vs -376.32% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

33.00

43.60

-24.31%

Operating Profit (PBDIT) excl Other Income

-13.50

-4.00

-237.50%

Interest

0.10

0.20

-50.00%

Exceptional Items

10.80

-10.50

202.86%

Consolidate Net Profit

-11.90

-7.00

-70.00%

Operating Profit Margin (Excl OI)

-638.60%

-263.50%

-37.51%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -24.31% vs -54.01% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -70.00% vs -237.25% in Dec 2023

All Annual Results

Company CV

About Retractable Technologies, Inc.

Retractable Technologies, Inc.

Pharmaceuticals & Biotechnology

Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.

Company Coordinates

Company Details

511 Lobo Ln , LITTLE ELM TX : 75068-5295

Tel: 1 972 2941010

Registrar Details

Retractable Technologies, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Retractable Technologies, Inc.?

Watch in Real-Time

What does Retractable Technologies, Inc. do?

Who are in the management team of Retractable Technologies, Inc.?

Is Retractable Technologies, Inc. overvalued or undervalued?

Is Retractable Technologies, Inc. technically bullish or bearish?

Compare Retractable Technologies, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Retractable Technologies, Inc.

Company Coordinates